Drug intelligence / Profile preview

048-006

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

048-006 is a novel human monoclonal antibody designed to target the epidermal growth factor receptor (EGFR). EGFR is frequently overexpressed in various epithelial cancers, including hepatocellular carcinoma (HCC), making it a compelling target for both cancer imaging and therapy. This antibody is being investigated as a noninvasive imaging probe to assess the uptake of therapeutic anti-EGFR antibodies in HCC.

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on 048-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 048-006.

Explore the full profile